A 2026 partnering scan of Crossbeta Biosciences B.V, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Emiliem, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Cytogel Pharma, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Connect Biopharma Holdings Limited, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Gnubiotics Sciences, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Abintus Bio, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Arrogene, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Cyclo Therapeutics, Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of AAVANTGARDE BIO, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Hebei Zhitong Biopharmaceutical, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Advanced Proteome Therapeutics Corporation, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of GangaGen, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.